What changed
$NBIX — BUY 📊
Neurocrine Biosciences, Inc.
🎯 Q2 2026 | Rev $1B | EPS $1.94 vs $1.70 🟢
💡 Consensus underestimated NBIX's margin improvement and Ingrezza resilience. The variant view is that earnings beats will continue, and pipeline optionality is undervalued, leading to multiple expansion from current 20.8x P/E toward 25x as growth accelerates.
📉 Reward/Risk: 3.1:1
🏢 Business Quality: 8/10
📊 Valuation: cheap — trailing annualized P/E 20.8x vs biotech peer median 25-30x for similar growth profiles; EV/Sales ~30x but justified by high margins; DCF...
🔮 Catalyst: Q2 2026 earnings report and potential pipeline data at upcoming medical conferences
💰 Entry: $161.44, stop $145, target $212.5
⚖️ Buy NBIX on post-earnings undervaluation; the 14% EPS beat is not fully priced, and Q2 catalysts can drive re-rating toward $212 in 3 months.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NBIX0624